We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients (MICONOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00905268
Recruitment Status : Completed
First Posted : May 20, 2009
Results First Posted : June 27, 2016
Last Update Posted : June 27, 2016
Sponsor:
Information provided by (Responsible Party):

May 19, 2009
May 20, 2009
October 20, 2015
June 27, 2016
June 27, 2016
April 2006
January 2010   (Final data collection date for primary outcome measure)
Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52 [ Time Frame: Baseline and week 52 ]
The International Cooperative Ataxia Rating Scale (ICARS) is a commonly used evaluation and is composed of four clinical sub-scores involving the following: posture and gait, limb coordination, speech and oculomotor function.The ICARS score is the total sum of the sub scores and ranges from 0 to 100, with 100 indicative of the most severely affected outcome.
Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52 [ Time Frame: 1 year ]
Complete list of historical versions of study NCT00905268 on ClinicalTrials.gov Archive Site
  • Absolute Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline Assessment to Week 52 [ Time Frame: Baseline and week 52 ]
    The Friedreich Ataxia Rating Scale (FARS) is made up of a measure of ataxia, and activities of daily living subscale and a neurological subscale. The scores from the three subscales are added to generate a total score ranging from 0 to 159, with a higher score indicating a greater level of disability.
  • Proportion of Patients Improving (Responding) on ICARS by a Clinically Relevant Margin [ Time Frame: week 52 ]

    The International Cooperative Ataxia Rating Scale (ICARS) is a commonly used evaluation and is composed of four clinical sub-scores involving the following: posture and gait, limb coordination, speech and oculomotor function.The ICARS score is the total sum of the sub scores and ranges from 0 to 100, with 100 indicative of the most severely affected outcome.

    ICARS Responder Analysis at Week 52: Percentage of subjects Improving by 2.5 Points or More.

  • Proportion of Patients Improving on Left Ventricular Peak Systolic Strain Rate or Showing a Reduction in Left Ventricular Mass Index (LVMI) With no Worsening in Strain Rate [ Time Frame: 1 year ]
    (In the statistical analysis sub-population presenting with cardiac involvement as defined by the FRDA cardiomyopathy criteria)
  • Change in Peak Systolic Strain Rate From Baseline to Week 52 [ Time Frame: 1 year ]
    Mean Change of Peak systolic longitudinal strain rate (PSLSR) from Baseline to Week 52 in subjects with cardiac involvement (FRDA-CM criteria), where positive value in PSLSR is a deterioration and negative value an improvement.
  • Change in Peak Workload From Baseline to Week 52 [ Time Frame: 1 year ]

    Assessed by a modified exercise test, in a subset of patients able to undertake this.

    Wpeak has been calculated from the following formula: Workload last fully completed stage + (seconds completed in last stage / 60 * (4 [if arm ergonometry] or 10 [if leg ergonometry])).

  • Absolute and percent change in Friedreich's Ataxia Rating Scale (FARS) scores from baseline assessment to Week 52 [ Time Frame: 1 year ]
  • Percent change in International Cooperative Ataxia Rating Scale (ICARS) scores from baseline assessment to Week 52 [ Time Frame: 1 year ]
  • Percent change in Left Ventricular Mass Index (LVMI) from baseline assessment to Week 52 [ Time Frame: 1 year ]
  • Change in Peak Systolic Strain Rate From Baseline to Week 52 [ Time Frame: 1 year ]
  • Change in peak workload from baseline to Week 52, as assessed by a modified exercise test, in a subset of patients able to undertake this [ Time Frame: 1 year ]
Not Provided
Not Provided
 
A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients
A Phase III Double-blind, Randomised, Placebo-controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
The purpose of this trial is to study the efficacy, safety and tolerability of idebenone in 12 months of treatment in children and adults with Friedreich's Ataxia. This is a randomised placebo-controlled double-blind trial conducted in Europe. Efficacy outcomes include measures of neurological impairment and function, and measures of the heart.

Idebenone, a short-chain analogue of Co-enzyme Q10 (CoQ10), has the potential to moderate underlying causes of Friedreich's Ataxia through its antioxidant activity and its role as an electron carrier in the respiratory chain promoting mitochondrial ATP production.

The current 12-month placebo-controlled treatment study in 232 patients aims to confirm the positive effect of idebenone on neurological function, as for instance observed in the recent 48-patient, 6-month NICOSIA study in children, using the International Cooperative Ataxia Rating Scale (ICARS) and the newly developed Friedreich's Ataxia Rating Scale (FARS).

In addition, the study aims to confirm the positive effect on cardiomyopathy associated with FRDA observed in several small studies. Cardiac anatomy and function will be assessed using echocardiography, tissue Doppler imaging and cardiac MRI methods in patients with FRDA cardiomyopathy. In addition exercise capacity, measured as peak workload, will be assessed in patients able to comply with a modified exercise protocol.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Friedreich's Ataxia
  • Drug: idebenone
    12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
  • Drug: Placebo
    12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
  • Experimental: Group A: Idebenone
    Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
    Intervention: Drug: idebenone
  • Experimental: Group B: Idebenone
    Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
    Intervention: Drug: idebenone
  • Experimental: C: Idebenone
    Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
    Intervention: Drug: idebenone
  • Placebo Comparator: D: Placebo
    placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
232
January 2010
January 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Documented diagnosis of FRDA with confirmed FRDA mutations
  • Patients 8 years of age or older at baseline
  • Patients with body weight ≥ 25kg
  • Patients who in the opinion of the investigator are able to comply with the requirements of the study, including swallowing the medication
  • Negative urine pregnancy test at screening and at baseline (women of childbearing potential)

Exclusion Criteria:

  • Treatment with idebenone or Coenzyme Q10 within the past 1 month
  • Pregnancy and/or breast-feeding
  • Clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal of SGOT, SGPT, or creatinine
  • Past or present history of abuse of drugs or alcohol
Sexes Eligible for Study: All
8 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Belgium,   France,   Germany,   Netherlands,   United Kingdom
 
 
NCT00905268
SNT-III-001
Yes
Not Provided
Not Provided
Santhera Pharmaceuticals
Santhera Pharmaceuticals
Not Provided
Principal Investigator: Nick Wood, Professor Dept of Molecular Neuroscience, Institute of Neurology. The National Hospital, University college London.
Santhera Pharmaceuticals
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP